Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Andrei Mircea Catarig"'
Autor:
Thozhukat Sathyapalan, Andrei-Mircea Catarig, Patrick Holmes, Jean-François Yale, Ulrik Bodholdt, Sergiu Catrina, Alice Clark, Neda Rajamand Ekberg, Umut Erhan, Søren Tang Knudsen, Joanne Liutkus, Bernd Schultes, Gottfried Rudofsky
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 10, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/c62708ce246d49819106d68b235a3c72
Autor:
Markus Menzen, Tina Landsvig Berentzen, Andrei-Mircea Catarig, Sebastian Pieperhoff, Jörg Simon, Stephan Jacob
Publikováno v:
Experimental and Clinical Endocrinology & Diabetes. 131:205-215
Context Efficacy and safety of once-weekly semaglutide in type 2 diabetes were established in the phase 3 SUSTAIN trials, which included patients across the continuum of type 2 diabetes care. It is useful to complement these findings with real-world
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3742a40a8135a3ddf667ac607e486f83
https://doi.org/10.1055/a-2007-2061
https://doi.org/10.1055/a-2007-2061
Autor:
Ildiko Lingvay, Emre Yildirim, Richard E Pratley, Vanita R Aroda, Andrei-Mircea Catarig, Jörg Lüdemann, Adie Viljoen
Publikováno v:
BMJ Open, Vol 10, Iss 11 (2020)
Objective In SUSTAIN 7, once-weekly semaglutide demonstrated superior glycated haemoglobin (HbA1c) and body weight (BW) reductions versus once-weekly dulaglutide in subjects with type 2 diabetes (T2D). This post hoc analysis investigated the impact o
Externí odkaz:
https://doaj.org/article/c6f1b297825643f89d227b421dbb6cff
Autor:
Kamel Mohammedi, Narimene Belhatem, Tina Landsvig Berentzen, Andrei‐Mircea Catarig, Louis Potier
Publikováno v:
Diabetes, Obesity and Metabolism.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07b7cb658efe9d9522e0949392e85297
https://doi.org/10.1111/dom.15045
https://doi.org/10.1111/dom.15045
Autor:
null Raffaele Napoli, null Cesare Berra, null Andrei‐Mircea Catarig, null Chiara Di Loreto, null Emily Donatiello, null Tina Landsvig Berentzen, null Dario Pitocco, null Francesco Giorgino
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aae78dd1ad4d78b1bb436fe914fdfa1b
https://doi.org/10.1111/dom.15020/v2/response1
https://doi.org/10.1111/dom.15020/v2/response1
Autor:
Raffaele Napoli, Cesare Berra, Andrei‐Mircea Catarig, Chiara Di Loreto, Emily Donatiello, Tina Landsvig Berentzen, Dario Pitocco, Francesco Giorgino
Aims: SURE Italy, a multicentre, prospective, open-label, observational, real-world study, investigated once-weekly (OW) semaglutide in patients with type 2 diabetes (T2D) in routine clinical practice. Materials and methods: Adults with T2D and ≥1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7998f80bc279bd225aff36d6307322e6
https://hdl.handle.net/11588/913425
https://hdl.handle.net/11588/913425
Autor:
Andrei Mircea Catarig, Alena Machell, Alice Clark, Karan Bozkurt, Patrick Holmes, Heather Elizabeth Bell, Thozhukat Sathyapalan
Publikováno v:
Diabetes Therapy
Introduction Once-weekly (OW) semaglutide was associated with clinically relevant improvements in glycaemic control and body weight versus comparators in the SUSTAIN randomised controlled trials (RCTs). SURE UK, which is one of a series of individual
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdfbb1cfce2c8769d549951cd11455dd
http://europepmc.org/articles/PMC8475854
http://europepmc.org/articles/PMC8475854
Autor:
Markus Menzen, Tina Landsvig Berentzen, Andrei-Mircea Catarig, Sebastian Pieperhoff, Jörg Simon, Stephan Jacob
Publikováno v:
Hand in Hand zum Ziel – einfach.besser.messbar www.diabeteskongress.de.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a1839cb1b1bf59bd3ce2320a6c61e29
https://doi.org/10.1055/s-0042-1746340
https://doi.org/10.1055/s-0042-1746340
Autor:
Gottfried Rudofsky, Andrei-Mircea Catarig, Umut Erhan, Rashmi Jain, Søren Tang Knudsen, Ponnusamy Saravanan, Jean-François Yale
Publikováno v:
Nephrology Dialysis Transplantation. 37
BACKGROUND AND AIMS The SURE programme of observational real-world studies is investigating once-weekly (OW) subcutaneous semaglutide in routine clinical practice across a diverse type 2 diabetes (T2D) patient population, including those with chronic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::def9033d8c4a6449cd0d4e9a43f14a1b
https://doi.org/10.1093/ndt/gfac126.003
https://doi.org/10.1093/ndt/gfac126.003